Actively Recruiting
Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer
Led by Poitiers University Hospital · Updated on 2025-12-24
1000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the role of circulating tumor DNA (ctDNA) and exosomes in digestive, gynecological, and breast cancers. These markers can be detected through simple blood tests and provide information about tumor genetics, treatment response, and disease progression. The study aims to assess the diagnostic, prognostic, and predictive value of ctDNA and exosomes in a large prospective group of patients, building on recent advances in molecular biology and sensitive techniques like Next Generation Sequencing (NGS). The study involves collecting blood samples at various times during patients' cancer treatment, including at the start, during therapy, at progression or relapse, and during treatment breaks. The focus is on analyzing ctDNA for mutations and genetic alterations that may influence therapy, as well as studying the composition of exosomes. Only one study group is involved, with patients undergoing blood draws for these analyses. Participants will have their blood collected for ctDNA and exosome analysis and will be monitored over an average of 12 months. Researchers will evaluate outcomes such as mortality related to ctDNA levels, diagnostic value of ctDNA and exosomes, their prognostic impact, predictive value for treatment response or resistance, and detection of molecular changes. This study is observational with no masking, and participants' health and treatment progress will be tracked throughout.
CONDITIONS
Brief Title
Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Proven or suspected digestive, gynecological, or breast cancer requiring chemotherapy or immunotherapy
- Adult patient (18 years or older)
- Covered by a Social Security scheme or equivalent
- Able to understand and provide informed consent for the study
You will not qualify if you...
- Unable or unwilling to understand or sign the informed consent due to language or psychological reasons
- History of another cancer within the 5 years prior to enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants provide blood samples at different times during their treatment to assess circulating tumor DNA and exosomes.
Multiple visits for blood sample collection during treatment
Trial Site Locations
Total: 1 location
1
CHU POitiers
Poitiers, France
Actively Recruiting
Research Team
C
Camille EVRARD, PHD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here